Sotagliflozin protects kidney and heart in patients with type 2 diabetes and chronic kidney disease

Nov. 30, 2023
Results from the phase 3 SCORED trial indicate that sotagliflozin protects kidney and heart health in individuals with type 2 diabetes and chronic kidney disease.

An exploratory analysis recently uncovered the effects of sotagliflozin, a dual SGLT1 and 2 inhibitor, in patients with type 2 diabetes and chronic kidney disease. The research was presented at ASN Kidney Week 2023 November 1–November 5.

The analysis involved data from the SCORED trial, a phase 3, double-blind, placebo-controlled study that randomized 10,584 patients with type 2 diabetes, chronic kidney disease, and cardiovascular factors to receive sotagliflozin or placebo. The outcomes assessed included kidney and cardiorenal composites derived using laboratory values.

Over a median follow-up of 16 months, 223 events were identified, and sotagliflozin reduced the risk of the composite of sustained ≥50% decline in estimated glomerular filtration rate, estimated glomerular filtration rate <15 mL/min/1.73m2, dialysis, or kidney transplant by 38%. Sotagliflozin also reduced the risk of a cardiorenal composite outcome (the above composite plus cardiovascular- or kidney-related death) by 23%.

American Society of Nephrology (ASN) release on Newswise